Literature DB >> 11843096

Iron and Parkinson's disease.

Benjamin Wolozin1, Natalie Golts.   

Abstract

Multiple studies implicate iron in the pathophysiology of Parkinson's disease (PD). In the brains of patients with PD, iron levels are elevated and the levels of iron-binding proteins are abnormal. Iron has been suspected to contribute to PD because Fe(II) is known to promote oxidative damage. Recent studies suggest that an additional mechanism by which iron might contribute to PD is by inducing aggregation of the alpha-synuclein, which is a protein that accumulates in Lewy bodies in PD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11843096     DOI: 10.1177/107385840200800107

Source DB:  PubMed          Journal:  Neuroscientist        ISSN: 1073-8584            Impact factor:   7.519


  24 in total

Review 1.  Oxidative stress and NAD+ in ischemic brain injury: current advances and future perspectives.

Authors:  W Ying; Z-G Xiong
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

Review 2.  Molecular control of vertebrate iron homeostasis by iron regulatory proteins.

Authors:  Michelle L Wallander; Elizabeth A Leibold; Richard S Eisenstein
Journal:  Biochim Biophys Acta       Date:  2006-05-17

3.  Dopamine D₂/D₃ agonists with potent iron chelation, antioxidant and neuroprotective properties: potential implication in symptomatic and neuroprotective treatment of Parkinson's disease.

Authors:  Sanjib Gogoi; Tamara Antonio; Subramanian Rajagopalan; Maarten Reith; Julie Andersen; Aloke K Dutta
Journal:  ChemMedChem       Date:  2011-05-12       Impact factor: 3.466

4.  Dynamics of tyrosine hydroxylase mediated regulation of dopamine synthesis.

Authors:  Poorvi Kaushik; Fredric Gorin; Shireen Vali
Journal:  J Comput Neurosci       Date:  2007-04       Impact factor: 1.621

5.  Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease.

Authors:  Balaram Ghosh; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2010-03-11       Impact factor: 7.446

6.  Late-life hemoglobin and the incidence of Parkinson's disease.

Authors:  Robert D Abbott; G Webster Ross; Caroline M Tanner; Julie K Andersen; Kamal H Masaki; Beatriz L Rodriguez; Lon R White; Helen Petrovitch
Journal:  Neurobiol Aging       Date:  2010-08-14       Impact factor: 4.673

7.  Multifunctional D2/D3 agonist D-520 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregates.

Authors:  Gyan Modi; Chandrashekhar Voshavar; Sanjib Gogoi; Mrudang Shah; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  ACS Chem Neurosci       Date:  2014-07-09       Impact factor: 4.418

8.  A low-molecular-weight ferroxidase is increased in the CSF of sCJD cases: CSF ferroxidase and transferrin as diagnostic biomarkers for sCJD.

Authors:  Swati Haldar; 'alim J Beveridge; Joseph Wong; Ajay Singh; Daniela Galimberti; Barbara Borroni; Xiongwei Zhu; Janis Blevins; Justin Greenlee; George Perry; Chinmay K Mukhopadhyay; Christine Schmotzer; Neena Singh
Journal:  Antioxid Redox Signal       Date:  2013-04-16       Impact factor: 8.401

Review 9.  Promotion of cellular NAD(+) anabolism: therapeutic potential for oxidative stress in ageing and Alzheimer's disease.

Authors:  Nady Braidy; Gilles Guillemin; Ross Grant
Journal:  Neurotox Res       Date:  2008 May-Jun       Impact factor: 3.911

10.  Overdosing on iron: Elevated iron and degenerative brain disorders.

Authors:  Santosh R D'Mello; Mark C Kindy
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.